Definitive Healthcare Corp. · NASDAQ:DH
Definitive Healthcare — Q1 2026 Earnings Presentation
18 slides from Definitive Healthcare's earnings presentation, May 7, 2026
Slide 1: First quarter 2026 earnings presentation
First quarter 2026 earnings presentation May 7, 2026
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation includes forward-looking statements that reflect our current views with respect to future events and financial For additional discussion of factors that could impact our operational and financial results, refer to our annual
Slide 3: Q1'26
Q1’26 3
Slide 4: Q1 2026 performance highlights
Q1 2026 performance highlights “Definitive Healthcare started 2026 on a solid note, with financial results at or above the high end of our guidance ranges. We continue to make (6%) progress against each of our strategic pillars and are realizing some Revenue Decline YoY positive early indications of
Slide 5: Q1 performance and guidance
Q1 performance and guidance $ Millions, except Q1’26 Guidance Range percentages and per share info Revenue $55.9 $54.0 - $56.0 § Q1 results were at or above the high end of the % growth YoY (6%) (9%) - (5%) guided range. Adjusted Operating Income1 $12.9 $9.5 - $10.5 § Q1 non-GAAP profit exceeded exp
Slide 6: Q1 2026 results
Q1 2026 results P&L on non-GAAP basis § Q1 performance at or above high end of guided ranges § Adjusted EBITDA margin improvement YoY driven by broader expense efficiency, higher capitalized software spend and a timing gap of a new data source Revenue mix $ Millions Subscription, 96% mix Q1'26 Q1'25
Slide 7: Q1 2026 cash flow and balance sheet highlights
Q1 2026 cash flow and balance sheet highlights $ Millions Q1'26 Q1'25 YoY Change Cash Flow from Operations $11.6 $26.1 (56%) Unlevered Free Cash Flow1 $18.0 $22.9 (22%) $49.9 million TTM uFCF5 $ Millions Q1'26 Q1'25 YoY Change Cash, cash equivalents & short-term investments2 $178.1 $200.7 (11%) Tota
Slide 8: Guidance
Guidance 8
Slide 9: Q2 and FY 2026 guidance
Q2 and FY 2026 guidance As of May 7, 2026 $ MILLIONS, except Second Quarter 2026 Full Year 2026 percentages and per share info Revenue $55.0 - $56.0 $220.0 - $226.0 § We are maintaining our full year revenue guide, which reflects our view of the year under existing % change YoY (9%) - (8%) (9%) - (6
Slide 10: Appendix
Appendix Non-GAAP reconciliations & basis of presentation 10
Slide 11: Key shareholder statistics
Key shareholder statistics Public Shares Minority Interest Key shareholder statistics as of 3/31/2026 (Class A) (Class B) Combined Comments Sponsor ownership (as-if converted) 1 63,935,333 13,843,158 77,778,491 § 114K Class B shares were exchanged into Class A public shares in the quarter Management
Slide 12: Reconciliation from GAAP gross profit and margin to adjusted gross profit and margin
Reconciliation from GAAP gross profit and margin to adjusted gross profit and margin THREE MONTHS ENDED MARCH 31, $ THOUSANDS 2026 2025 $ % GAAP Gross Profit $41,650 $43,760 ($2,110) (5%) Amortization of intangible assets resulting from acquisition- 3,487 3,153 334 11% related purchase accounting ad
Slide 13: Reconciliation from GAAP to non-GAAP operating expenses
Reconciliation from GAAP to non-GAAP operating expenses THREE MONTHS ENDED MARCH 31, $ THOUSANDS 2026 2025 $ % GAAP Sales & Marketing $19,578 $20,653 ($1,075) (5%) Equity-based compensation (951) (1,179) $228 (19%) Other non-core items 1 (16) - ($16) (100%) Non-GAAP Sales & Marketing $18,611 $19,474
Slide 14: Reconciliation from net loss to adjusted operating income and adjusted net income
Reconciliation from net loss to adjusted operating income and adjusted net income THREE MONTHS ENDED MARCH 31, $ THOUSANDS 2026 2025 $ % GAAP Net loss ($192,354) ($155,093) ($37,261) 24% Interest expense, net 1,332 381 951 >100% Income tax benefit (3,435) (10,886) 7,451 (68%) Loss on partial extingu
Slide 15: Reconciliation from net loss to adjusted EBITDA
Reconciliation from net loss to adjusted EBITDA THREE MONTHS ENDED MARCH 31, $ THOUSANDS 2026 2025 $ % GAAP Net loss ($192,354) ($155,093) ($37,261) 24% Interest expense, net 1,332 381 951 >100% Income tax benefit (3,435) (10,886) 7,451 (68%) Loss on partial extinguishment of debt - 507 (507) (100%)
Slide 16: Reconciliation from cash flow from operations to unlevered free cash flow
Reconciliation from cash flow from operations to unlevered free cash flow THREE MONTHS ENDED MARCH 31, $ THOUSANDS 2026 2025 $ % Cash Flow from Operations $11,564 $26,066 ($14,502) (56%) Cash interest expense 2,472 2,242 $230 10% Transaction, integration, and restructuring expenses paid in 4,116 1,7
Slide 17: Schedule of transaction, integration and restructuring expense and other non-core items
Schedule of transaction, integration and restructuring expense and other non-core items THREE MONTHS ENDED MARCH 31, $ THOUSANDS 2026 2025 Merger and acquisition due diligence and transaction costs $352 $1,178 Integration costs (2,169) 557 Fair value adjustment for contingent consideration - (690) R
Slide 18: Non-GAAP financial measures / Basis of presentation
Non-GAAP financial measures / Basis of presentation Enterprise Customers: Customers generating more than $100,000 in ARR (as the term is defined below). RPO: Represents the amount of contracted future revenue that has not yet been recognized, including both deferred revenue and non-cancelable contra
Definitive Healthcare — Q1 2026 Earnings Presentation on 6ix